Literature DB >> 1629827

Giant cell arteritis and polymyalgia rheumatica in a region of Finland: an epidemiologic, clinical and pathologic study, 1984-1988.

P Franzén1, S Sutinen, J von Knorring.   

Abstract

The occurrence of giant cell arteritis (GCA) (considering temporal arteritis and polymyalgia rheumatica as its manifestations) was investigated in Western Nyland, Finland. Between 1984 and 1988 54 patients were diagnosed in a population of about 44,500. Fourteen patients (26%) had biopsy proven arteritis at the initial evaluation, and 2 patients became biopsy positive during followup. The retrospectively determined annual incidence of GCA in a 44 month period was 22.5/10(5) in the whole population, and 69.8/10(5) in residents aged 50 years or older. The corresponding figures of a prospective 16 month study were 30.4/10(5) and 94.4/10(5). The incidence rates of the prospective study are higher than those reported in comparable studies. Polymyalgia rheumatica, occurring alone or combined with cranial symptoms, was the most frequent manifestation of GCA, being present in 87% of patients.

Entities:  

Mesh:

Year:  1992        PMID: 1629827

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  14 in total

1.  Epidemiology of giant cell arteritis in an Arab population: a 22-year study.

Authors:  Neil R Miller
Journal:  Br J Ophthalmol       Date:  2007-06       Impact factor: 4.638

Review 2.  The geo-epidemiology of temporal (giant cell) arteritis.

Authors:  Jennifer L Lee; Stanley M Naguwa; Gurtej S Cheema; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

Review 3.  Diagnosis and treatment of giant cell arteritis.

Authors:  Fabrizio Cantini; Laura Niccoli; Carlotta Nannini; Michele Bertoni; Carlo Salvarani
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

4.  Diagnostic performance of ¹⁸F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a systematic review and meta-analysis.

Authors:  Florent L Besson; Jean-Jacques Parienti; Boris Bienvenu; John O Prior; Sylvie Costo; Gerard Bouvard; Denis Agostini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-05-11       Impact factor: 9.236

Review 5.  Giant cell arteritis: a review.

Authors:  Pravin Patil; Niral Karia; Shaifali Jain; Bhaskar Dasgupta
Journal:  Eye Brain       Date:  2013-03-09

6.  New features of disease after diagnosis in 6 forms of systemic vasculitis.

Authors:  Peter C Grayson; David Cuthbertson; Simon Carette; Gary S Hoffman; Nader A Khalidi; Curry L Koening; Carol A Langford; Kathleen Maksimowicz-McKinnon; Paul A Monach; Philip Seo; Ulrich Specks; Steven R Ytterberg; Peter A Merkel
Journal:  J Rheumatol       Date:  2013-08-01       Impact factor: 4.666

7.  Effect of diabetes mellitus on giant cell arteritis.

Authors:  Anne S Abel; Arseniy P Yashkin; Frank A Sloan; Michael S Lee
Journal:  J Neuroophthalmol       Date:  2015-06       Impact factor: 3.042

8.  The incidence of giant cell arteritis in Olmsted County, Minnesota, over a 60-year period 1950-2009.

Authors:  A K Chandran; P D Udayakumar; C S Crowson; K J Warrington; E L Matteson
Journal:  Scand J Rheumatol       Date:  2015-01-21       Impact factor: 3.641

Review 9.  Giant cell arteritis. Epidemiology and treatment.

Authors:  E Nordborg; R Andersson; B A Bengtsson
Journal:  Drugs Aging       Date:  1994-02       Impact factor: 3.923

10.  The risk of polymyalgia rheumatica in older adults with gout: a Medicare claims study.

Authors:  Jasvinder A Singh; John D Cleveland
Journal:  Rheumatol Adv Pract       Date:  2018-06-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.